Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before starting any supplement, particularly if you have a known mushroom allergy, a bleeding disorder, or are scheduled for surgery.

TL;DR

• Lion’s mane (Hericium erinaceus, yamabushitake in Japanese) contains two families of compounds associated with NGF induction in preclinical models: hericenones (from the fruiting body) and erinacines (from the mycelium). The human trial record is limited but directionally consistent.
• The Mori et al. 2009 randomized, double-blind, placebo-controlled trial (30 Japanese adults aged 50–80 with mild cognitive impairment, 3 g/day yamabushitake powder for 16 weeks) found significantly higher Hasegawa Dementia Scale scores in the supplemented group compared to placebo. Scores declined during the 4-week wash-out after stopping supplementation.
• Saitsu et al. 2019 reported modest but statistically significant improvements in cognitive scores in older adults receiving 3 g/day Hericium erinaceus for three months compared to placebo.
• Both trials used small samples. They establish a directional signal on short-term cognitive score changes in older adults — not a treatment claim for cognitive disease.
• Lion’s mane also contains β-glucans and is a meaningful dietary source of ergothioneine, both studied for separate longevity-adjacent mechanisms.
• The fruiting-body-versus-mycelium sourcing question is practically significant: published MCI trial material used dried fruiting body; many commercial products sold in North America use grain-cultured mycelium, which may have lower hericenone content.

The question most lion’s mane buyers are working through

Lion’s mane has moved from specialty Japanese health food stores to mainstream supplement aisles with notable speed. The search interest tells the story: “lion’s mane benefits,” “lion’s mane Japan,” and “hericium erinaceus longevity” are all growing, driven by neuroplasticity research and a broader wellness market interested in functional mushrooms.

The reasonable buyer question is not “does lion’s mane work” — that framing is too broad to answer honestly. It is: what does the human evidence actually show, at what dose, in what population, and how do I connect those trials to a product I can actually purchase?

Yamabushitake in Japan: traditional use and modern context

Hericium erinaceus is called yamabushitake (山伏茸) in Japanese — named after the shaggy, white-bearded appearance of the fruiting body, thought to resemble the fur garments worn by yamabushi mountain ascetics. It grows naturally on broadleaf hardwoods across Japan, China, and Korea, and has been cultivated as both a culinary mushroom and a traditional medicinal plant for centuries in East Asian practice.

In Japan, yamabushitake is eaten as a food — the flavor is mild, often compared to seafood — and used in traditional Kampo medicine. Modern cultivation has made it widely available at Japanese grocery stores, both fresh and dried. Research interest in its neurological associations emerged primarily from Japanese academic laboratories in the late 1980s and 1990s, when researchers identified specific compounds responsible for NGF-inducing activity in cell culture models.

The NGF pathway: hericenones, erinacines, and the preclinical record

Nerve Growth Factor (NGF) is a neurotrophin — a protein that supports the growth, differentiation, and maintenance of neurons, particularly cholinergic neurons in the basal forebrain. Cholinergic neuron function is associated with memory and learning; reduced NGF signaling is observed in Alzheimer’s disease pathology and age-related cognitive decline. NGF does not cross the blood-brain barrier on its own, which is why the field has been interested in finding small molecules that stimulate endogenous NGF synthesis from within the brain.

Two compound families in lion’s mane appear associated with NGF induction in preclinical models:

Hericenones (isolated from the fruiting body) stimulate NGF synthesis in cultured mouse glial cells at low concentrations in laboratory settings. They are not NGF themselves; they appear to upregulate the transcription of NGF in surrounding cells.

Erinacines (isolated from the mycelium, particularly erinacine A, B, and C) also stimulate NGF synthesis in vitro and in vivo in rodent models. Erinacine A has been shown in rodent studies to be small enough to cross the blood-brain barrier — which has made it a focus of more recent research into how oral supplementation might reach the central nervous system.

Neither hericenones nor erinacines have been directly measured in human brain or plasma after oral supplementation in the published cognitive trials. The mechanism is well-characterized preclinically and biologically plausible in humans, but the inferential chain from laboratory NGF induction to human cognitive outcomes has not yet been closed by direct measurement in people.

Mori 2009: the RCT on mild cognitive impairment

The foundational human trial is Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T, “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial,” published in Phytotherapy Research (2009;23(3):367–372).

Design: 30 Japanese adults aged 50–80 meeting diagnostic criteria for mild cognitive impairment (MCI) were randomized to either yamabushitake fruiting body powder (3 g/day in tablet form) or matched placebo for 16 weeks. The primary outcome was the Hasegawa Dementia Scale (HDS-R), a validated Japanese screening instrument for cognitive assessment.

Results: The yamabushitake group showed significantly higher HDS-R scores at weeks 8, 12, and 16 compared to the placebo group, with differences reaching statistical significance (p < 0.05) at each time point. During a 4-week wash-out period after stopping supplementation, scores in the yamabushitake group declined toward the placebo group’s range — a reversal pattern consistent with an effect that may require continued supplementation to maintain.

No serious adverse events were reported. The tolerability profile within this trial and dose window was acceptable.

Three calibrations before reading too much into these results:

The sample of 30 adults is small. Effect sizes from small trials are less stable than those from larger studies; replication across independent research groups matters substantially for this kind of finding.

The Hasegawa Dementia Scale is a screening tool designed to detect dementia, not to measure nuanced cognitive changes in MCI. It may not be the most sensitive instrument for the kind of subtle shifts the NGF hypothesis predicts.

The wash-out reversal is clinically interesting, but it also raises questions about whether the observed change reflected a direct cognitive effect or other confounders (placebo-related expectancy patterns, test familiarity, measurement variation across time points). A larger trial with a longer, better-powered wash-out arm would clarify this.

The participants had a specific clinical profile — diagnosed MCI in Japanese adults 50–80. The findings are not automatically extensible to healthy younger adults without cognitive impairment.

Saitsu 2019: the second cognitive trial

Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K, “Improvement of cognitive functions by oral intake of Hericium erinaceus,” published in Biomedical Research (2019;40(4):125–131), added a second randomized controlled observation in an older adult population.

This trial enrolled 31 older adults without an MCI diagnosis but with mild self-reported cognitive concerns. Participants received 3 g/day of Hericium erinaceus powder or placebo for three months. Cognitive assessment used a version of the Mini-Mental State Examination (MMSE) alongside subsidiary measures.

The supplemented group showed modest but statistically significant improvements on the assessed cognitive measures compared to the placebo group over the trial period. The magnitude of improvement was small. As with Mori 2009, sample size limits confidence in generalizing the finding.

What Saitsu 2019 adds to the evidence base: directional consistency with Mori 2009 in a slightly different population (no MCI diagnosis) and with a different cognitive assessment instrument. Two independent trials pointing the same direction is a meaningful step, even when both samples are small.

What neither trial establishes: any benefit in healthy adults with no cognitive concerns, at doses below 3 g/day, or over time periods longer than four months. Both trials are preliminary in humans, and the broader evidence base does not yet include large-scale replication.

β-glucans and ergothioneine: the longevity-adjacent dimension

Lion’s mane shares two compound categories with other medicinal mushrooms that have separate longevity-adjacent research tracks.

β-glucans — polysaccharides that form part of the fungal cell wall — are present in lion’s mane and have been studied for immune marker modulation in both preclinical and small clinical contexts. The immune modulation data specific to lion’s mane β-glucans is largely preclinical; stronger clinical data for β-glucans comes from other fungal sources (notably Grifola frondosa and Lentinula edodes). For lion’s mane buyers interested in this dimension, the available evidence supports interest but not strong clinical claims.

Ergothioneine is a naturally occurring amino acid produced by fungi and certain bacteria; mushrooms are the most significant dietary source for most humans, and lion’s mane contains meaningful ergothioneine concentrations, alongside shiitake, oyster, and porcini mushrooms.

Observational data from multiple cohort analyses links higher plasma ergothioneine levels to lower markers of frailty and, in some analyses, lower cardiovascular-related mortality. The proposed mechanism involves ergothioneine acting as a mitochondrial antioxidant via a dedicated cellular transporter (OCTN1) that concentrates it in erythrocytes, liver, and brain — tissues where oxidative stress is clinically relevant. Intervention trial data establishing that raising ergothioneine through supplementation changes mortality outcomes does not yet exist. The observational associations are intriguing but have not cleared the bar of randomized trial confirmation.

For the broader context on Japanese mushrooms in the longevity supplement landscape, the Choju Lab Amazon supplement guide covers the functional mushroom category alongside NMN, CoQ10, and other high-search compounds.

Fruiting body versus mycelium: the supplement quality question

This is the most practically consequential distinction when comparing lion’s mane products, and it is frequently underspecified on labels.

Both Mori 2009 and Saitsu 2019 used dried fruiting body powder — the mushroom’s visible reproductive structure, where hericenone concentration is highest. Many commercially available lion’s mane supplements in the US and Europe use mycelium cultured on a grain substrate (typically oats or brown rice). After harvest, the grain is dried and ground along with the mycelium; the resulting powder contains varying proportions of grain starch and actual fungal material.

Products made this way can have substantially lower concentrations of hericenones per gram than fruiting body extracts, because the grain substrate dilutes the final product and hericenones are not present in the grain itself. Erinacines are found in the mycelium, which is a point in favor of mycelial products — but the starch dilution problem applies to the overall active compound density regardless of which compound family you are targeting.

What to look for when comparing products:

• “Fruiting body” specification — source material most consistent with the published MCI trials
• Beta-glucan percentage stated — a proxy for actual fungal material proportion versus grain substrate
• Absence of “starch” in supplement facts — presence suggests grain substrate makes up a significant fraction
• Extract ratio or hericenone standardization — standardized products exist; they are fewer in number and typically more expensive, but they give you more information about what you are actually ingesting

Full-spectrum and dual-extract products that include both fruiting body and mycelium material are available; they are not well represented in published trials yet, but theoretically provide both hericenones and erinacines.

Side effects and what to watch for

The published trial record on lion’s mane safety is short, based on small samples. Mori 2009 reported no serious adverse events at 3 g/day over 16 weeks. Saitsu 2019 similarly found no notable adverse events.

Outside of formal trials:

Mushroom allergy or sensitivity — lion’s mane is a mushroom. Isolated case reports document contact dermatitis from handling fresh lion’s mane, and there are anecdotal accounts of respiratory sensitivity in individuals with other mushroom sensitivities. The relationship of these reactions to oral supplementation is not clearly characterized in published literature; people with known mushroom allergies should discuss supplementation with a clinician before starting.

Platelet aggregation — some mushroom extracts, including lion’s mane, have been noted in small studies and in vitro models to inhibit platelet aggregation. This is a potential concern for individuals on anticoagulant or antiplatelet medications (warfarin, aspirin, clopidogrel), or ahead of surgical procedures.

Pregnancy and lactation — no clinical safety data exists for these populations.

Long-term safety beyond four to six months is not established in published human data. The culinary food-use history in Japan provides indirect reassurance for dietary quantities; supplement-level concentrations over extended periods remain undercharacterized.

How to find a product worth trying

The most reliable filters when comparing lion’s mane supplements: Does the label specify fruiting body as the source material? Is a beta-glucan percentage stated? Is there a certificate of analysis from a third-party lab available from the brand?

Search lion’s mane fruiting body extract capsules on Amazon — look for products that explicitly name fruiting body as the source and state a beta-glucan percentage on the Supplement Facts panel.

Search dried lion’s mane fruiting body on Amazon — the culinary form consumed in Japan is available dried from specialty retailers; cooking it as a food is the form with the longest traditional use history.

Search lion’s mane mushroom powder organic on Amazon — powder forms can be mixed into coffee, tea, or food; prioritize labels that specify fruiting body content and state a beta-glucan percentage.

iHerb carries a comparable range with user review data. Filtering for “fruiting body” in the search narrows to the most trial-consistent product category.

For context on how lion’s mane fits alongside other Japan-linked adaptogens, see Ashwagandha vs. Japanese Adaptogens: Reishi, Ashitaba, and Eucommia for a calibrated comparison of the functional plant and mushroom categories.

Who should not take lion’s mane without a clinical conversation

• Anyone on anticoagulant or antiplatelet medications (warfarin, aspirin, clopidogrel): potential platelet interaction warrants discussion with a prescribing clinician before starting.
• Anyone scheduled for surgery within two weeks: precautionary, given limited data on platelet effects.
• Anyone with a known mushroom allergy or history of adverse reactions to mushroom-derived supplements: the safety profile in this population is not established.
• Pregnant or breastfeeding individuals: no clinical safety data available.

If cognitive symptoms are a genuine concern rather than a general wellness interest, a physician evaluation is the appropriate starting point. The brain-imaging, biomarker, and clinical context a clinician can provide is not replaceable by supplement selection.

Lion’s mane sits in the category of a calibrated-evidence bet: a biologically plausible mechanism, two small but directionally consistent trials in Japanese older adult populations, and a food-use safety history that extends decades. It does not sit in the category of a proven intervention for cognitive disease. If you start, use a fruiting body-sourced product at the 3 g/day dose studied in the trials, set a defined trial period (12–16 weeks), and track one or two simple personal metrics before deciding whether to continue.

---

Sources: Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.” Phytotherapy Research. 2009;23(3):367–372. Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. “Improvement of cognitive functions by oral intake of Hericium erinaceus.” Biomedical Research. 2019;40(4):125–131. Friedman M. “Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion’s Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds.” Journal of Agricultural and Food Chemistry. 2015;63(32):7108–7123.